雍禾醫療(02279.HK)公佈年度業績 除利息、税項、折舊及攤銷前實現盈利1.41億元
格隆匯3月27日丨雍禾醫療(02279.HK)公佈，截至2024年12月31日止年度，集團的收入增加1.5%至人民幣1,804.5百萬元。集團的毛利增加8.7%至人民幣1,084.2百萬元。毛利率由上年度的56.1%增加至截至2024年12月31日止年度的60.1%。
集團的淨虧損由上年度的人民幣546.7百萬元收窄58.6%至截至2024年12月31日止年度的淨虧損人民幣226.6百萬元。截至2023年12月31日止年度集團的除利息、税項、折舊及攤銷前虧損為人民幣183.6百萬元，而截至2024年12月31日止年度則錄得除利息、税項、折舊及攤銷前盈利為人民幣141.0百萬元。
公司一直專注於毛髮醫療服務市場，並構建了以「雍禾醫療」為核心，由專業植髮品牌「雍禾植髮」、醫療養固品牌「史雲遜」、女性美學植髮品牌「雍禾發之初」及醫學假髮品牌「哈發達」等組成的全產業鏈品牌矩陣。截至2024年12月31日，公司在全國63個城市擁有66家植髮醫療機構，在上海、廣州、深圳擁有8家史雲遜健發機構，為中國最大及覆蓋城市最廣的連鎖毛髮醫療集團。報吿期內，公司服務患者總人數逾12萬人。
截至2024年12月31日止年度，接受公司植髮手術的患者人數為59,655人，其中，接受「雍享」服務的患者人數顯著提升，較上年同期增加16.3%。
為進一步優化資源配置與服務價值，公司對醫療養固產品和套餐結構進行了戰略性調整，將原有的生活級護理套餐升級為醫療級聯合治療套餐，報吿期內，醫療養固人均消費由人民幣4,934元提升17.0%至人民幣5,773元。同時，公司完善了術後複查體系，為顧客量身定製專屬的術後養固療程，提高養固服務復購率至28.4%。截至2024年12月31日止年度，接受公司醫療養固服務的患者人數為77,222人。
集團始終堅持以醫療為本質的服務理念，貫徹「待之以醫、賦之以美」的原則，強調好醫生在毛髮醫療服務中的重要作用，以進一步鞏固自身的領先地位，引領毛髮醫療行業高質量發展。截至2024年12月31日止，集團建立了一支由1,401人組成的專業醫療團隊。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app！
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
